Injection devices for Rheumatoid Arthritis patients: Comparing usability of two autoinjectors
By Timothy Visich We partnered with Merck & Co., Inc and Samsung Bioepis and conducted a simulated-use comparative study on two autoinjectors used for the treatment of rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is often treated by effective biologics delivered in different types of injection devices. RA patients, who are often limited in dexterity capabilities, are sometimes prescribed self-injection devices to deliver injections on themselves. Using an injection device for self-delivery can be a hard task for RA patients to complete, and even painful depending on the device being used. Recently, Merck & Co., Inc and Samsung Bioepis have developed the Brenzys autoinjector with the goal of improving the self-injection experience for RA patients. Brenzys (left) and Enbrel (right) While delivering a biosimilar of etanercept (Enbrel), the Brenzys device offers the following advantages: Eliminates the need for pressing down on an injection ...